Document Detail


Cannabidiol is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19.
MedLine Citation:
PMID:  23318708     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The present study investigated the inhibitory effect of cannabidiol (CBD), a major constituent of marijuana, on the catalytic activity of cytochrome P450 2C19 (CYP2C19). (S)-Mephenytoin 4'-hydroxylase activities of human liver microsomes (HLMs) and recombinant CYP2C19 were inhibited by CBD in a concentration-dependent manner (IC(50) = 8.70 and 2.51 µM, respectively). Omeprazole 5-hydroxylase and 3-O-methylfluorescein O-demethylase activities in recombinant CYP2C19 were also strongly inhibited by CBD (IC(50) = 1.55 and 1.79 µM, respectively). Kinetic analysis for inhibition revealed that CBD showed a mixed-type inhibition against (S)-mephenytoin 4'-hydroxylation by recombinant CYP2C19. To clarify the structural requirements for CBD-mediated CYP2C19 inhibition, the effects of CBD-related compounds on CYP2C19 activity were examined. Olivetol inhibited the (S)-mephenytoin 4'-hydroxylase activity of recombinant CYP2C19 with the IC(50) value of 15.3 µM, whereas d-limonene slightly inhibited the activity (IC(50) > 50 µM). The inhibitory effect of CBD-2'-monomethyl ether (IC(50) = 1.88 µM) on CYP2C19 was comparable to that of CBD, although the inhibitory potency of CBD-2',6'-dimethyl ether (IC(50) = 14.8 µM) was lower than that of CBD. Cannabidivarin, possessing a propyl side chain, showed slightly less potent inhibition (IC(50) = 3.45 µM) as compared with CBD, whereas orcinol and resorcinol did not inhibit CYP2C19 activity at all. These results indicate that CBD caused potent CYP2C19 inhibition, in which one free phenolic hydroxyl group and the pentyl side chain of CBD may play important roles.
Authors:
Rongrong Jiang; Satoshi Yamaori; Yasuka Okamoto; Ikuo Yamamoto; Kazuhito Watanabe
Related Documents :
23650368 - X-ray structure of an adomet radical activase reveals an anaerobic solution for formylg...
24304348 - Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histo...
23618168 - New approach for the potentiometric-enzymatic assay of reversible-competitive enzyme in...
24397738 - Discovery of 7-tetrahydropyran-2-yl chromans: beta-site amyloid precursor protein cleav...
1825928 - Domains of yeast plasma membrane and atpase-associated glycoprotein.
11563948 - Proteinase inhibitors from the medicinal leech hirudo medicinalis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-15
Journal Detail:
Title:  Drug metabolism and pharmacokinetics     Volume:  -     ISSN:  1880-0920     ISO Abbreviation:  Drug Metab. Pharmacokinet.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101164773     Medline TA:  Drug Metab Pharmacokinet     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Service Users' Perceptions About Their Hospital Admission Elicited by Service User-Researchers or by...
Next Document:  Three-dimensional organisation of RNA-processing machinery in avian growing oocyte nucleus.